Lycia Therapeutics Stock
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Sign up today and learn more about Lycia Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Lycia Therapeutics Stock
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
Funding History
| June 2020 | $50.0M |
|---|---|
| September 2021 | $70.0M |
Management
Board Member
Timothy Anderson
Board Member
Clare Ozawa
Vice President, Head of Biology
Sarah McWhirter
Chief Scientific Officer
Steve Staben
Founder
Carolyn Bertozzi
Chief Executive Officer
Aetna Wun Trombley
Press
globenewswire - Feb, 28 2022
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officerbiospace - Sep, 10 2021
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Venturesprnewswire - Aug, 25 2021
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degradersbusinesswire - Jun, 18 2020
Versant Ventures Launches Lycia Therapeutics with $50 MillionEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
